Agios Pharmaceuticals, Inc. (AGIO) vs Mineralys Therapeutics, Inc. (MLYS)

A side-by-side comparison of Agios Pharmaceuticals, Inc. and Mineralys Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — AGIO vs MLYS

growth of $100 · dividends reinvested · last 4y
AGIO +8.5% (+2.1%/yr)MLYS +26.4% (+6.0%/yr)MLYS compounded faster over this window
50100150200250Start $100202420252026$109$126
AGIO MLYS

AGIO vs MLYS: by the numbers

  • •MLYS is the larger company ($1.96B vs $1.90B market cap).
  • •Both run net losses; MLYS's is the smaller (0.00% vs -418.24% net margin).

Metrics side by side

Valuation

MetricAGIOMLYS
P/S ratio19.35N/A
P/B ratio1.863.55

Profitability

MetricAGIOMLYS
Gross margin78.67%0.00%
Operating margin-873.87%0.00%
Net margin-418.24%0.00%
ROE-40.09%-63.45%
ROIC-44.21%-57.17%

Growth (annualized)

MetricAGIOMLYS
Revenue CAGR (5Y)4.54%N/A
Total return CAGR (5Y)-6.59%N/A

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.